▶ 調査レポート

Aβモノクローナル抗体医薬品の世界市場見通し2023年-2029年

• 英文タイトル:Aβ Monoclonal Antibody Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。Aβモノクローナル抗体医薬品の世界市場見通し2023年-2029年 / Aβ Monoclonal Antibody Drug Market, Global Outlook and Forecast 2023-2029 / MRC2312MG00938資料のイメージです。• レポートコード:MRC2312MG00938
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、86ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥481,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥721,500 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界のAβモノクローナル抗体医薬品市場規模と予測を収録しています。・世界のAβモノクローナル抗体医薬品市場:売上、2018年-2023年、2024年-2029年
・世界のAβモノクローナル抗体医薬品市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のAβモノクローナル抗体医薬品市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アデュカヌマブ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

Aβモノクローナル抗体医薬品のグローバル主要企業は、Eisai、 Biogen、 Eli Lilly & Co.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、Aβモノクローナル抗体医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のAβモノクローナル抗体医薬品市場:タイプ別、2018年-2023年、2024年-2029年
世界のAβモノクローナル抗体医薬品市場:タイプ別市場シェア、2022年
・アデュカヌマブ、レカネマブ、ドナネマブ

世界のAβモノクローナル抗体医薬品市場:用途別、2018年-2023年、2024年-2029年
世界のAβモノクローナル抗体医薬品市場:用途別市場シェア、2022年
・病院、診療所

世界のAβモノクローナル抗体医薬品市場:地域・国別、2018年-2023年、2024年-2029年
世界のAβモノクローナル抗体医薬品市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるAβモノクローナル抗体医薬品のグローバル売上、2018年-2023年
・主要企業におけるAβモノクローナル抗体医薬品のグローバル売上シェア、2022年
・主要企業におけるAβモノクローナル抗体医薬品のグローバル販売量、2018年-2023年
・主要企業におけるAβモノクローナル抗体医薬品のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Eisai、 Biogen、 Eli Lilly & Co.

*************************************************************

・調査・分析レポートの概要
Aβモノクローナル抗体医薬品市場の定義
市場セグメント
世界のAβモノクローナル抗体医薬品市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のAβモノクローナル抗体医薬品市場規模
世界のAβモノクローナル抗体医薬品市場規模:2022年 VS 2029年
世界のAβモノクローナル抗体医薬品市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのAβモノクローナル抗体医薬品の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のAβモノクローナル抗体医薬品製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:アデュカヌマブ、レカネマブ、ドナネマブ
Aβモノクローナル抗体医薬品のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院、診療所
Aβモノクローナル抗体医薬品の用途別グローバル売上・予測

・地域別市場分析
地域別Aβモノクローナル抗体医薬品市場規模 2022年と2029年
地域別Aβモノクローナル抗体医薬品売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Eisai、 Biogen、 Eli Lilly & Co.
...

This research report provides a comprehensive analysis of the Aβ Monoclonal Antibody Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Aβ Monoclonal Antibody Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Aβ Monoclonal Antibody Drug, challenges faced by the industry, and potential opportunities for market players.
The global Aβ Monoclonal Antibody Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Aβ Monoclonal Antibody Drug market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Aβ Monoclonal Antibody Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Aβ Monoclonal Antibody Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Aβ Monoclonal Antibody Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Aβ Monoclonal Antibody Drug market.
Market Overview: The report provides a comprehensive overview of the Aβ Monoclonal Antibody Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Aducanumab, Lecanemab), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Aβ Monoclonal Antibody Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Aβ Monoclonal Antibody Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Aβ Monoclonal Antibody Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Aβ Monoclonal Antibody Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Aβ Monoclonal Antibody Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Aβ Monoclonal Antibody Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Aβ Monoclonal Antibody Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Aβ Monoclonal Antibody Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Aβ Monoclonal Antibody Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Aducanumab
Lecanemab
Donanemab
Market segment by Application
Hospital
Clinic
Global Aβ Monoclonal Antibody Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Eisai
Biogen
Eli Lilly & Co.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Aβ Monoclonal Antibody Drug, market overview.
Chapter 2: Global Aβ Monoclonal Antibody Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Aβ Monoclonal Antibody Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Aβ Monoclonal Antibody Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Aβ Monoclonal Antibody Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Aβ Monoclonal Antibody Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Aβ Monoclonal Antibody Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Aβ Monoclonal Antibody Drug Overall Market Size
2.1 Global Aβ Monoclonal Antibody Drug Market Size: 2022 VS 2029
2.2 Global Aβ Monoclonal Antibody Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Aβ Monoclonal Antibody Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Aβ Monoclonal Antibody Drug Players in Global Market
3.2 Top Global Aβ Monoclonal Antibody Drug Companies Ranked by Revenue
3.3 Global Aβ Monoclonal Antibody Drug Revenue by Companies
3.4 Global Aβ Monoclonal Antibody Drug Sales by Companies
3.5 Global Aβ Monoclonal Antibody Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Aβ Monoclonal Antibody Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Aβ Monoclonal Antibody Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Aβ Monoclonal Antibody Drug Players in Global Market
3.8.1 List of Global Tier 1 Aβ Monoclonal Antibody Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Aβ Monoclonal Antibody Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Aβ Monoclonal Antibody Drug Market Size Markets, 2022 & 2029
4.1.2 Aducanumab
4.1.3 Lecanemab
4.1.4 Donanemab
4.2 By Type – Global Aβ Monoclonal Antibody Drug Revenue & Forecasts
4.2.1 By Type – Global Aβ Monoclonal Antibody Drug Revenue, 2018-2023
4.2.2 By Type – Global Aβ Monoclonal Antibody Drug Revenue, 2024-2029
4.2.3 By Type – Global Aβ Monoclonal Antibody Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Aβ Monoclonal Antibody Drug Sales & Forecasts
4.3.1 By Type – Global Aβ Monoclonal Antibody Drug Sales, 2018-2023
4.3.2 By Type – Global Aβ Monoclonal Antibody Drug Sales, 2024-2029
4.3.3 By Type – Global Aβ Monoclonal Antibody Drug Sales Market Share, 2018-2029
4.4 By Type – Global Aβ Monoclonal Antibody Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Aβ Monoclonal Antibody Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application – Global Aβ Monoclonal Antibody Drug Revenue & Forecasts
5.2.1 By Application – Global Aβ Monoclonal Antibody Drug Revenue, 2018-2023
5.2.2 By Application – Global Aβ Monoclonal Antibody Drug Revenue, 2024-2029
5.2.3 By Application – Global Aβ Monoclonal Antibody Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Aβ Monoclonal Antibody Drug Sales & Forecasts
5.3.1 By Application – Global Aβ Monoclonal Antibody Drug Sales, 2018-2023
5.3.2 By Application – Global Aβ Monoclonal Antibody Drug Sales, 2024-2029
5.3.3 By Application – Global Aβ Monoclonal Antibody Drug Sales Market Share, 2018-2029
5.4 By Application – Global Aβ Monoclonal Antibody Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Aβ Monoclonal Antibody Drug Market Size, 2022 & 2029
6.2 By Region – Global Aβ Monoclonal Antibody Drug Revenue & Forecasts
6.2.1 By Region – Global Aβ Monoclonal Antibody Drug Revenue, 2018-2023
6.2.2 By Region – Global Aβ Monoclonal Antibody Drug Revenue, 2024-2029
6.2.3 By Region – Global Aβ Monoclonal Antibody Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Aβ Monoclonal Antibody Drug Sales & Forecasts
6.3.1 By Region – Global Aβ Monoclonal Antibody Drug Sales, 2018-2023
6.3.2 By Region – Global Aβ Monoclonal Antibody Drug Sales, 2024-2029
6.3.3 By Region – Global Aβ Monoclonal Antibody Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Aβ Monoclonal Antibody Drug Revenue, 2018-2029
6.4.2 By Country – North America Aβ Monoclonal Antibody Drug Sales, 2018-2029
6.4.3 US Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.4.4 Canada Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.4.5 Mexico Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Aβ Monoclonal Antibody Drug Revenue, 2018-2029
6.5.2 By Country – Europe Aβ Monoclonal Antibody Drug Sales, 2018-2029
6.5.3 Germany Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.4 France Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.5 U.K. Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.6 Italy Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.7 Russia Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.8 Nordic Countries Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.5.9 Benelux Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Aβ Monoclonal Antibody Drug Revenue, 2018-2029
6.6.2 By Region – Asia Aβ Monoclonal Antibody Drug Sales, 2018-2029
6.6.3 China Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.6.4 Japan Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.6.5 South Korea Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.6.6 Southeast Asia Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.6.7 India Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Aβ Monoclonal Antibody Drug Revenue, 2018-2029
6.7.2 By Country – South America Aβ Monoclonal Antibody Drug Sales, 2018-2029
6.7.3 Brazil Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.7.4 Argentina Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Aβ Monoclonal Antibody Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Aβ Monoclonal Antibody Drug Sales, 2018-2029
6.8.3 Turkey Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.8.4 Israel Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Aβ Monoclonal Antibody Drug Market Size, 2018-2029
6.8.6 UAE Aβ Monoclonal Antibody Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eisai
7.1.1 Eisai Company Summary
7.1.2 Eisai Business Overview
7.1.3 Eisai Aβ Monoclonal Antibody Drug Major Product Offerings
7.1.4 Eisai Aβ Monoclonal Antibody Drug Sales and Revenue in Global (2018-2023)
7.1.5 Eisai Key News & Latest Developments
7.2 Biogen
7.2.1 Biogen Company Summary
7.2.2 Biogen Business Overview
7.2.3 Biogen Aβ Monoclonal Antibody Drug Major Product Offerings
7.2.4 Biogen Aβ Monoclonal Antibody Drug Sales and Revenue in Global (2018-2023)
7.2.5 Biogen Key News & Latest Developments
7.3 Eli Lilly & Co.
7.3.1 Eli Lilly & Co. Company Summary
7.3.2 Eli Lilly & Co. Business Overview
7.3.3 Eli Lilly & Co. Aβ Monoclonal Antibody Drug Major Product Offerings
7.3.4 Eli Lilly & Co. Aβ Monoclonal Antibody Drug Sales and Revenue in Global (2018-2023)
7.3.5 Eli Lilly & Co. Key News & Latest Developments
8 Global Aβ Monoclonal Antibody Drug Production Capacity, Analysis
8.1 Global Aβ Monoclonal Antibody Drug Production Capacity, 2018-2029
8.2 Aβ Monoclonal Antibody Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Aβ Monoclonal Antibody Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Aβ Monoclonal Antibody Drug Supply Chain Analysis
10.1 Aβ Monoclonal Antibody Drug Industry Value Chain
10.2 Aβ Monoclonal Antibody Drug Upstream Market
10.3 Aβ Monoclonal Antibody Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Aβ Monoclonal Antibody Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer